SG Americas Securities LLC Raises Position in Janux Therapeutics, Inc. $JANX

SG Americas Securities LLC grew its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 175.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,817 shares of the company’s stock after acquiring an additional 50,802 shares during the period. SG Americas Securities LLC’s holdings in Janux Therapeutics were worth $1,101,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Squarepoint Ops LLC boosted its holdings in shares of Janux Therapeutics by 230.0% in the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock valued at $4,379,000 after acquiring an additional 132,121 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of Janux Therapeutics by 21.1% in the third quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock valued at $8,443,000 after acquiring an additional 60,188 shares in the last quarter. Congress Asset Management Co. purchased a new stake in shares of Janux Therapeutics in the third quarter valued at about $1,363,000. Readystate Asset Management LP boosted its holdings in shares of Janux Therapeutics by 38.0% in the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock valued at $23,472,000 after acquiring an additional 264,423 shares in the last quarter. Finally, Jump Financial LLC boosted its holdings in shares of Janux Therapeutics by 142.9% in the second quarter. Jump Financial LLC now owns 228,430 shares of the company’s stock valued at $5,277,000 after acquiring an additional 134,400 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 2.7%

JANX stock opened at $14.53 on Thursday. The company has a market cap of $883.86 million, a P/E ratio of -7.94 and a beta of 2.82. Janux Therapeutics, Inc. has a 52 week low of $12.12 and a 52 week high of $35.34. The company’s 50-day moving average price is $13.72 and its 200 day moving average price is $18.76.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The company had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $0.08 million. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

JANX has been the topic of a number of research analyst reports. Cantor Fitzgerald decreased their price objective on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Barclays decreased their price objective on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Clear Str downgraded shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Guggenheim decreased their price objective on shares of Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.